drugset / Trial / NCT06455761
68Ga-DOTA-NI-FAPI04 PET/CT in Patients With Various Types of Cancer
RandomizedParallel-groupOpen-labelDiagnostic
Summary
As a novel radiotracer targeting fibroblast activation protein (FAP), 68Ga-DOTA-NI-FAPI04 is a novel agent incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a FAP-targeting. In this study, we observed the diagnostic performance of 68Ga-DOTA-NI-FAPI04 PET/CT in patients with different types of cancer, and compared its imaging results with those of 68Ga-FAPI or 18F-FDG PET/CT.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2025-04-01
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 18F-FDG | Diagnostic / imaging agent | 3.7 mbq/kg | Intravenous |
| Subject | 68Ga-DOTA-NI-FAPI04 | Diagnostic / imaging agent | — | Intravenous |
| Subject | FAPI GA-68 | Diagnostic / imaging agent | — | Intravenous |